Targeted regulation of certain processes of glucose metabolism reprogramming in bladder cancer cells (such as targeting HK2) can inhibit the proliferation of bladder cancer cells, and abnormal glucose metabolism may contribute to drug resistance to chemotherapy drugs. The gene discussed is HK2; the disease is urinary bladder carcinoma.